Glucose Homeostasis and Apple Polyphenols

PreDiabetes Clinical Trial

Official title: The Effects of Apple Polyphenol Supplementation on Glucose Homeostasis in Prediabetic Individuals

Status Terminated

Clinical Trial Summary

The primary objective is to investigate the effect of apple polyphenol supplementation for 12 weeks on glucose homeostasis in prediabetic individuals. Further, this study has three secondary objectives: 1) to investigate whether daily supplementation at breakfast and dinner with apple polyphenols for 12 weeks affects the rhythm of glucose uptake over the day and reduces fasting glucose levels and postprandial glucose peaks; 2) to determine the effect of daily supplementation with apple polyphenols for 12 weeks on biomarkers of metabolic health; 3) to assess whether daily supplementation with apple polyphenols for 12 weeks alters fecal SCFA concentrations and fecal microbiota composition.

Clinical Trial Description

Study Design: 45 Prediabetic adults will be included in a double-blind randomized placebo-controlled trial. All volunteers will be subjected to a 12-week period during which an apple polyphenol supplement or placebo will be ingested at breakfast and dinner. An intervention period of 12 weeks with a third visit half way of the intervention has been chosen. After 6 weeks and at the end of the study microbiota composition is measured since dietary intervention of at least 6 weeks is required to be able to measure changes in microbial composition and metabolic health. The third visit will be scheduled to monitor protocol compliance and check the well-being of subjects. Concomitant medication will be recorded as well as adverse events. In addition, subjects will be reminded about the intake of the investigational product and difficulties to compliance will be discussed. Subjects will perform an oral glucose tolerance test, blood samples are taken and fecal samples will be collected at the start of the study, half-way and at the end of the intervention period. The oral glucose tolerance test will be performed to determine glucose tolerance. During the OGTT blood glucose samples will be collected at 30, 60, 90 and 120 minutes in order to determine area under the curve of glucose as primary endpoint for the glucose tolerance. The blood samples are taken to measure whole blood glucose, serum insulin, HbA1c, metabolic profile, antioxidant levels (protocol compliance) and SCFA. The fecal samples are collected to assess the fecal microbiota composition and fecal SCFA concentration. Finally, at the start of the intervention, and after the third visit an Abott FreeStyle Libre Pro Continuous Glucose Monitoring (CGM)(Hoofddorp, The Netherlands) sensor is inserted. The Abott FreeStyle Libre Pro CGM sensor will be injected and worn for a period of 14 days after which the subjects will visit for collecting the data for continuous glucose monitoring with a recorder. The Abott FreeStyle Libre Pro is intended for use with type 2 diabetic individuals but a recent study has validated its use in prediabetic individuals (50).The baseline continuous glucose monitoring needs to be completed before the intervention will be started. Screening and pre-testing: Prior to the study, volunteers' suitability to participate will be assessed in a single screening session. The participants will be asked to come to the laboratory in fasted state (i.e. no eating or drinking after 22:00h the night before; drinking water is allowed) After explaining all study procedures, written informed consent will be obtained from subjects willing to participate. A signed copy of the informed consent will be provided for the subject to keep. The subject's suitability for the trial will be confirmed by the inclusion/exclusion criteria (see section 4). During screening, body weight, height and BMI (using the equation BMI = body mass (kg)/height (m)2 ) will be assessed. Subjects will be asked to fill in a medical questionnaire enquiring about their general health, medical history, GI symptoms, use of medication and sports activities. HbA1C will be measured using an Abbott™ Afinion™ 2 Analyzer (Hoofddorp, The Netherlands). Subjects will be included based on the results from BMI, and the in- and exclusion criteria discussed in the medical questionnaire. Included subjects will be instructed to collect a fecal sample to determine microbial composition- and activity and SCFA concentration. A collection kit will be provided to take home that includes a toilet hat, instructions for collecting the specimen, a collection tube, and a biohazard mailing bag. A short questionnaire about the collection time and date will be included in the collection kit as well as a dietary recall questionnaire. Food records and stool characteristics will be scored with a questionnaire and handed in by the subject at visit 1 (pre-test), as well as a fecal donation to determine microbial composition- and activity and SCFA concentration. Test day: Volunteers will visit the laboratory on six occasions over a twelve-week period. All subjects will be asked to record their dietary intake at three consecutive days in a food diary and to consume similar foods during the experimental period. Participants will be asked to record this in a food diary and approximately match caloric intake on the day prior to the second test day and eat the same type of meal. For the oral glucose tolerance test (OGTT), participants will be asked to come to the laboratory in fasted state (i.e. no eating or drinking after 22:00h the night before; drinking water is allowed), the participants will receive a standardized meal ("Aviko meal pan", Aviko bv. The Netherlands) from the researchers and the participants need to consume this meal prior to the OGTT testing days. The meals that the participants receive have a similar macronutrient composition and energy density. In addition, the food intake during the 3 days before the OGTT is asked to be kept similar. Participants need to abstain from strenuous exercise to maintain muscle glycogen stores and alcohol consumption for at least 48 h. Subjects perform the following experimental protocol three times, prior to, 39 to 45 and 81 to 87 days after the start of the intervention period. On arrival at the laboratory, subjects will be placed in a semi-supine position whilst a resting blood sample is collected from an antecubital vein (venipuncture) inserting a BC-shielded IV catheter. After providing the fasted blood sample, subjects will consume a glucose rich drink (75 grams corrected for weight). At 30-minutes, 60-minutes, 90-minutes and 120-minutes additional blood samples will be taken. An Abott FreeStyle Libre Pro will be injected for continuous glucose monitoring. The subjects will be asked to wear an Abott FreeStyle Libre Pro sensor for a period of 14 days. Subjects will be asked to collect the first three fecal samples after the OGTT. For this collection, participants will receive feces collection materials and collect the samples by themselves. Intervention period: Following the first OGTT, participants start the intervention period. During this 12-week intervention period, subjects will consume a supplement twice a day at breakfast and at dinner. Supplements contain either apple polyphenols (see section 5), or control, according to the randomization scheme. The intervention products are detailed in chapter 6. To facilitate participant compliance with adhering to the intake requirements and investigate the effect of antioxidants on the circadian pattern of glucose homeostasis, participants are advised to align their oral study product dosing to the timing of breakfast and dinner. In addition, a physical activity diary will be completed. At baseline and after 6 and 12 weeks of intervention, the following measurements will be performed: three-day food record, physical activity questionnaire, Bristol stool scores and Gastrointestinal Symptoms Rating Scores and a fecal sample. Subjects will be asked to maintain their regular exercise schema. Subjects will not receive individual results after measuring the outcome parameters, except when there will be unexpected findings (e.g. abnormal clinical parameter). Subjects can only participate in this study if they are willing to be informed about relevant unexpected findings (e.g. abnormal clinical parameter). ;

Related Conditions & MeSH terms

• Glucose Intolerance
• Glucose Metabolism Disorders
• Impaired Glucose Tolerance
• Metabolic Diseases
• PreDiabetes
• Prediabetic State

• NCT number: NCT05951270
• Study type: Interventional
• Source: Maastricht University
• Status: Terminated
• Phase: N/A
• Start date: January 14, 2022
• Completion date: February 3, 2023